Abstract 50P
Background
As we enter an aging society, the number of elderly breast cancer patients is increasing. We assessed the prognostic factors of recurrence or metastasis for breast cancer patients over the age of 65 by analyzing the characteristics of tumor and long-term clinical outcomes.
Methods
Data were retrospectively analyzed for 286 breast cancer patients aged 65 years and older who underwent treatment in the Pusan national university hospital and Pusan national university Yangsan hospital from 2008 to 2014. Dividing two groups as the patients with event such as recurrence or metastasis and those who without it, the Cox regression model was used to examine the risk factors of recurrence or metastasis.
Results
Among 286 patients with invasive breast cancer, forty three patients (15.0%) have been found to have recurrence or distant metastasis during median follow-up period of 61 months. The poor prognosis was found in the advanced stage of breast cancer, patients without endocrine therapy and low Allred scores of estrogen receptor.Table: 50P
| Variable | Hazard ratio | P-value | 95% CI |
|---|---|---|---|
| Stage | 1.78 | <0.0001 | (1.39, 2.28) |
| Endocrine therapy | 0.04 | 0.0002 | (0.01, 0.23) |
| Estrogen receptor | 1.34 | 0.0076 | (1.08, 1.66) |
Conclusions
The advanced stage of breast cancer was poor prognosis in the elderly breast cancer patients. Moreover, endocrine therapy should be performed on elderly breast cancer patients with high Allred score of estrogen receptor because it is good for prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract